Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin (DAPA) Effects in HFpEF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study specific procedures.~* Male or female.~* Symptoms of dyspnea (NYHA II-III) with no non-cardiac or ischemia explanation.~* EF ≥ 50% + BMI ≥ 30 kg/m\^2~* Elevated pulmonary capillary wedge pressure (PCWP) during exercise (≥ 25 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized .~Exclusion Criteria:~* Type I diabetes.~* Type II diabetes with poor control (HgbA1C ≥ 10%).~* Recent hospitalization (\< 30 days) or revascularization (\< 90 days).~* Primary cardiomyopathy (such as amyloid).~* Constrictive pericarditis.~* Dyspnea due to primary lung disease or myocardial ischemia in the opinion of the investigator.~* Severe anemia (hemoglobin \< 9gm/dl.~* Significant left-sided valvular heart disease (\> mild stenosis, \> moderate regurgitation),~* Severe kidney disease (estimated glomerular filtration rate (GFR) \< 30) or liver disease,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin Group (Type: EXPERIMENTAL): Subjects with HFpEF will take the study drug dapagliflozin daily
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects with HFpEF will take a placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).